Expert Interview
A second discussion on the NASH treatment landscape and the potential of Altimmune's phase 1 study of pemvidutide, a GLP-1/glucagon dual receptor agonist.
Ticker(s): ALT, LLY, NVOInstitution: Amwell, Northside Hospital
- Board certified internist with a background in ER, pathology, hospital, and critical care
- Manages about 25-50 patients monthly with NASH
- Familiar with the potential treatments for NASH including Ozempic and have used it off label for years to ameliorate the condition
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
